ENDPOINTS NEWS44m
No­vo Nordisk to spend $1.2B for new rare dis­ease drug fac­to­ry in Den­mark
Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 ...
ENDPOINTS NEWS58m
Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...